news
Re-formulation of microbicidal lubricants will help protect from HIV
20 March 2017 | By Niamh Marriott, Junior Editor
Research published by BioMed Central’s open access journal AIDS Research and Therapy has investigated the use of lubricants...
List view / Grid view
HIV (Human Immunodeficiency Virus)
article
Gilead on HIV: New research, new treatments and the potential for a cure
15 March 2017 | By Mike Elliott, Vice President, Medical Affairs, Gilead Sciences
We caught up with Gilead’s Mike Elliott to find out the latest in HIV medication and whether a cure is finally within our reach…
article
‘End the stigma – everyone is at risk of HIV’ says TV’s Dr Christian Jessen
1 December 2016 | By Niamh Louise Marriott, Digital Editor
Embarrassing Bodies' Dr Christian Jessen talks debunking the stigma surround this pandemic disease and explains why it's OK if we don't find a cure...
news
ViiV Healthcare to evaluate injectable HIV treatment
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve...
news
FDA approves Roche’s blood screening assay for donor screening
24 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood...
news
Global dual-drug trial aims to advance HIV treatment
16 August 2016 | By ViiV Healthcare
ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had…
news
Triumeq demonstrates superior efficacy for treating women with HIV
19 July 2016 | By Victoria White, Digital Content Producer
Triumeq demonstrated superior efficacy compared with ATV/r plus TDF/FTC in 495 treatment-naïve women living with HIV...
news
EC grants marketing authorisation to Odefsey in HIV
23 June 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Gilead’s once-daily single tablet regimen Odefsey for the treatment of HIV-1 infection in certain patients...
news
3BNC117 opens door to potential new treatment for HIV
Researchers are developing a new kind of treatment, an antibody-based drug called 3BNC117, that may provide a better strategy for long-term control of HIV...
article
From HIV to oncology: widening access through flexible IP
28 April 2016 | By Jon Pender, VP Government Affairs, GSK
Jon Pender, GSK, discusses how a flexible and thoughtful approach to IP can help get medicines to the poorest and hardest-to-reach patients around the world...
news
EC grants marketing authorisation for two doses of Gilead’s Descovy
25 April 2016 | By Victoria White, Digital Content Producer
Descovy is the first new HIV backbone approved in Europe in more than a decade and represents an important advance in addressing the needs of patients...
news
Combined HIV and hepatitis C virus vaccination a step closer
13 April 2016 | By Victoria White, Digital Content Producer
A study has shown that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens...
news
Enrolment begins in trials of investigational anti-HIV antibody VRC01
7 April 2016 | By Victoria White, Digital Content Producer
Enrolment has started for two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection, VRC01...
news
NHS England to fund HIV treatment Rezolsta (darunavir/cobicistat)
30 March 2016 | By Victoria White
Darunavir/cobicistat is indicated for use in combination with other antiretroviral medications, for treating adults with HIV-1...
news
Janssen announces results from its ongoing LATTE-2 study
26 February 2016 | By Victoria White
The LATTE-2 study showed that a regimen of two investigational long-acting, intramuscular (IM) formulations of HIV medicines had comparable antiviral activity to 3-drug oral antiretroviral therapy in HIV-1 infected adults...
